Genprex doses first patient in Phase 2 expansion of Acclaim-3 trial for Reqorsa + Tecentriq in ES-SCLC

Genprex, Inc.

Phase 2 expansion will enroll ~50 patients at 10-15 U.S. sites; primary endpoint is 18-week progression-free survival rate.
Recommended Phase 2 dose of Reqorsa set at 0.12 mg/kg (highest Phase 1 dose), no dose-limiting toxicities observed.
Interim analysis planned after first 25 patients reach 18 weeks of follow-up; enrollment of initial 25 expected in H2 2025.
Acclaim-3 holds FDA Fast Track and Orphan Drug Designations for this extensive-stage small cell lung cancer indication.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.